A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma-Reference-Cited by-同舟云学术

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

Published:2019-02-04 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Milgrom Sarah A.,Elhalawani Hesham,Lee Joonsang,Wang Qianghu,Mohamed Abdallah S. R.,Dabaja Bouthaina S.,Pinnix Chelsea C.,Gunther Jillian R.,Court Laurence,Rao Arvind,Fuller Clifton D.^ORCID,Akhtari Mani,Aristophanous Michalis,Mawlawi Osama,Chuang Hubert H.,Sulman Erik P.,Lee Hun J.,Hagemeister Frederick B.,Oki Yasuhiro,Fanale Michelle,Smith Grace L.

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-37197-z.pdf

Reference56 articles.

1. Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363, 640–652, https://doi.org/10.1056/NEJMoa1000067 (2010).

2. Eich, H. T. et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28, 4199–4206, https://doi.org/10.1200/JCO.2010.29.8018 (2010).

3. Bonfante, V. et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15, 528–534, https://doi.org/10.1200/JCO.1997.15.2.528 (1997).